Navigation Links
A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
Date:11/20/2007

Siemens New MRI Systems Set Trends Again: MAGNETOM Verio Brings High- Resolution MRI to More Patients than Ever Before and MAGNETOM Essenza

Delivers the Newest Technology at the Most Affordable Price

MALVERN, Pa., Nov. 20 /PRNewswire-FirstCall/ -- Siemens Medical Solutions (http://www.usa.siemens.com/medical) is once again paving the way to increased access to essential imaging services with the introduction of two new magnetic resonance imaging (MRI) systems. At a 1.5 Tesla (T) magnetic field strength, the MAGNETOM(R) Essenza is the most affordable*, all-new MRI system on the market today. It was designed from the ground up to deliver high-field imaging at a low purchase price with similarly low installation and operational costs, compared with traditional MRI systems. The Essenza helps smaller healthcare facilities offer a new range of imaging services that were previously unavailable. Siemens new MAGNETOM Verio combines excellent image quality at 3T field strength and a 70-cm open bore that offers exceptional patient comfort in one solution. Additionally, the Verio increases access to high-field imaging services for patients who previously could not be imaged, like patients who are obese (up to 550 lbs.) or claustrophobic.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

Both of these systems offer Siemens unique Tim(TM) (Total imaging matrix) technology, which eliminates the need for patient repositioning and manual coil changes during scans, while significantly enhancing image quality. Tim technology can help MRI departments achieve advanced clinical and workflow capabilities.

Siemens will showcase these new systems along with a host of other MRI innovations at the 93rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RS
'/>"/>

SOURCE Siemens Medical Solutions
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
5. Siemens Extends Tender Offer for Acquisition of Dade Behring
6. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
7. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
8. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
9. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
10. Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment
11. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...n Eye Care Hospitals, one of the largest eye care ...its first branch here, with seven more in the offi...boration with K. Premraj, a prominent ophthalmic s...r of Prems' Eye Clinic. The first facility would h...
...on Americans have hypertension, that is, blood pre...n 120/80 mmHg). If untreated, it can lead to heart...anges are the first-stage treatment for the diseas...rescribed. Many patients with high blood pressure...
..., Dr Mukesh Haikerwal, today launched a unique web...//suffering fatigue, and make hospitals safer for ...Assessment website allows doctors to track their w...ng hours over a week, and determine whether their ...
...ent research published in The Lancet states that, ...y could help in faster information processing and ...emonstrated the effects of reduced levels of folat...omocysteine, in the blood of older adults which re...
Other Medicine News:Health News:Chinese Herb Shows Promise In Reducing Hypertension 2Health News:New AMA Tool Empowers Doctors to Work Safer Hours 2
(Date:10/8/2008)...ment in patients with pulmonary arterial hype...ve limited benefit for this debilitating, rap...e, -- Imatinib mesylate, available as Gleevec(R...inhibit protein associated with PAH, -- Novarti...e in PAH in 2009 EAST HANOVER, N.J., Oct. 8 ...
(Date:10/7/2008)...exas Cardiac Arrhythmia,Institute (TCAI) at St. Da...nly a few sites in the nation to participate in an...reat persistent atrial fibrillation. TCAI, an,inte...specializing in heart,rhythm disorders, is a partn...s Cardiovascular Consultants., "This is just anot...
(Date:10/7/2008)...-- CEL-SCI Corporation,(NYSE: CVM ) announced tod...reement (MTA) with the National Institutes of Heal...r. Francesco M. Marincola, M.D., to,investigate th...ironment,caused by CEL-SCI,s cancer drug Multikine...ease and Immunogentics Section, Department of Tran...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Finding the source 3A Cells that initiate a common infant tumor identified 21225 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 2Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 3Impact of Rising Gas Food Prices Felt Globally 21221 1Impact of Rising Gas Food Prices Felt Globally 21221 2Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 1Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 2
... ONCONASE for,Treatment of Neuroblastoma, BLOOMFIE...Alfacell Corporation today announced that new data... is active against naive and,chemoresistant neurob...vivo data published in Cancer,Letters (2007; Vol. ...ween Alfacell and Martin Michaelis, M.D., Ph.D., a...
...p; CEO of the Lupus,Foundation of America, Inc., W...- The Lupus,Foundation of America, Inc. and more t...iting the preliminary findings of the Phase,III cl...nt for,lupus kidney disease being tested by Asprev...ments for lupus patients is,critical because many ...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company 2
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: